6-[(2R,6S)-10-hydroxy-6,11,11-trimethyl-1,2,5,6-tetrahydro-4H-2,6-methanobenzo[d]azocine-3-carbonyl]-1,3-dihydroindol-2-one | 1155851-28-7

• 分子结构分类: 有机化合物
• 英文名称: 6-[(2R,6S)-10-hydroxy-6,11,11-trimethyl-1,2,5,6-tetrahydro-4H-2,6-methanobenzo[d]azocine-3-carbonyl]-1,3-dihydroindol-2-one
• 英文别名: 6-[(1S,9R)-6-hydroxy-1,13,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-10-carbonyl]-1,3-dihydroindol-2-one
• CAS: 1155851-28-7
• 化学式: C₂₄H₂₆N₂O₃
• 分子量: 390.482
• InChiKey: KMZPDXNKZCIVBT-YKSBVNFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
  申请人：Himmelsbach Frank

  公开号：US20110190262A1

  公开（公告）日：2011-08-04

  The present invention relates to compounds defined by formula I wherein the groups R 1 to R 3 , X, m, n and o are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及公式I所定义的化合物，其中R1至R3、X、m、n和o的定义如权利要求书中所述，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2220048B1

  公开（公告）日：2017-01-25
• US8859580B2
  申请人：——

  公开号：US8859580B2

  公开（公告）日：2014-10-14
• [EN] ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE<br/>[FR] DÉRIVÉS ARYL- ET HÉTÉROARYLCARBONYLES DE BENZOMORPHANES ET STRUCTURES LIÉES À CEUX-CI, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS ET LEUR UTILISATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009063061A2

  公开（公告）日：2009-05-22

  The present invention relates to compounds defined by formula (I), wherein the groups R1 to R3, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.